Tuesday, 23 June 2015 | Provisional Agenda |
| | | Please note all times are listed in EDT |
| | 10:00 | Predicting Protein Structure, Ligand Binding and Receptor Selectivity on GPCRs Hugo Gutierrez de Teran, Senior Researcher, Uppsala University, Sweden
G-protein coupled receptors (GPCRs) are one of the main target families in pharmaceutical research. We will present our computational pipeline to assist ligand design and receptor characterisation and show applications in different projects, where we collaborate with medicinal chemists, neuropharmacologists from the academy, as well as some pharmaceutical companies.
| 11:00 | Multiple Fragment Docking and Linking in Primary and Secondary Pockets of Dopamine Receptors Gyorgy Keseru, Scientific Advisor, Hungarian Academy of Sciences, Hungary
We developed a powerful computational methodology for the identification of highy affinity and subtype selective class A GPCR ligands. Its usefulness is demonstrated designing potent and selective dopamine D3 receptor ligands. | 12:00 | Development of Chemical Probes for Studying Cancer John Spencer, Professor, University of Sussex, United Kingdom
We will present the synthesis of privileged structure libraries and their applications against a range of biological targets. | 13:00 | | Keynote Presentation Open Innovation for Target and Lead Discovery Steve Rees, Vice President, AstraZeneca, United Kingdom
This talk will describe the objectives of the AstraZeneca Open Innovation platform to leverage the value in our compound collection to access novel compound collections and drug targets to increase the success of drug discovery. |
| 14:00 | Networking in Exhibition Hall | | 14:30 Poster Viewing | Session Sponsors |
| | 15:00 | Profiling Non-Clinical Drug Development Stella Stergiopoulos, Senior Project Manager, Tufts University School of Medicine, United States of America
The talk will open with a brief background on Tufts CSDD and our interest in non-clinical drug development. It will then talk about current trends in non-clinical development with respect to outsourcing.
| 16:00 | | Keynote Presentation Discovery and Optimization of a WDR5 Chemical Probe Rima Al-awar, Director, Ontario Institute For Cancer Research, Canada
The presentation will describe a collaborative effort between the Drug Discovery Program at OICR and the Structural Genomics Consortium that led to the identification of a chemical probe for WDR5. |
| 17:00 | Using Quantitative Systems Pharmacology for supporting rationally designed multi-target discovery projects in CNS R&D Hugo Geerts, Chief Scientific Officer, In Silico Biosciences Inc, United States of America
Mechanistic Disease Modeling builds complex computer models from preclinical animal physiology and human pathology and is calibrated with clinical data. The approach can support rationally designed multi-target drug discovery programs and significantly de-risk therapeutic projects for complex CNS disorders. | 18:00 | Complementing Corporate Solutions with Simple Tools to Enhance Compound Management Workflows Travis Mathewson, Principal Scientist, Pfizer Global Research and Development, United States of America
This talk will discuss the non-corporate tools and workflows integrated into compound management’s daily processes and the functions they support in order to ensure timely delivery of high quality products to better enable and streamline project screening efforts.
|
|